PRME
Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+10.37%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.56
From 52W high−38.03%
Volume4.17M
Market cap$694.67M
P/E (TTM)—
P/S (TTM)170.6x
Div yield—
Key dataOct 19, 2026
Open
$3.56
From 52W high
−38.03%
Volume
4.17M
Market cap
$694.67M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
P/E (TTM)
—
RSI (14)
57.3
MomentumView details →
1D Return
+10.37%
YTD Return
+10.23%
SummaryUpdated Jun 1, 2026
Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The company went public in October 2022 and focuses on developing genetic therapies using advanced gene editing technology. Prime Medicine represents a next-generation approach to gene editing, building upon the foundation of CRISPR technology to create more precise and versatile genetic modifications for treating various diseases.
Similar companies
Latest newsMore news →
Prime Medicine shares rose about 10.75% to $3.40 in after-hours trading.25d agoThe U.S. FDA cleared Prime Medicine's Investigational New Drug application for PM647 in alpha-1 antitrypsin deficiency.25d agoPrime Medicine, Inc. reported a Q2 2026 loss of $0.24 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.41 per share a year ago.74d ago